TEL AVIV, Israel, August 2, 2017 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company focused on oncology and immunology,
announced today that it will release its unaudited financial
results for the quarter ended June 30,
2017 on Tuesday, August 8,
2017, before the US markets open.
The Company will host a conference call on Tuesday, August 8, 2017 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer, and
David Malek, Chief Business Officer.
The conference call will be available via webcast and can be
accessed through the Investor Relations page of BioLineRx's
website. Please allow extra time prior to the call to visit the
site and download any necessary software to listen to the live
broadcast.
To dial into the conference call, please dial 1-888-668-9141
from the U.S. or +972-3-918-0609 internationally. A replay of the
conference call will be available approximately two hours after
completion of the live conference call at the Investor Relations
page of BioLineRx's website. A dial-in replay of the call will be
available until August 11, 2017;
please dial 1-877-456-0009 from the U.S. or +972-3-925-5946
internationally.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory acute myeloid leukemia (AML), is
in the midst of a Phase 2b study as an AML consolidation treatment
and a Phase 1b/2 study in pancreatic cancer, and is expected to
initiate a Phase 3 study in stem cell mobilization for autologous
transplantation; and AGI-134, an immunotherapy treatment in
development for multiple solid tumors, which is expected to
initiate a first-in-man study in the first half of 2018. In
addition, BioLineRx has a strategic collaboration with Novartis
Pharma AG for the co-development of selected Israeli-sourced novel
drug candidates; a collaboration agreement with MSD (known as Merck
in the US and Canada), on the
basis of which the Company has initiated a Phase 2a study in
pancreatic cancer using the combination of BL-8040 and Merck's
KEYTRUDA®; and a collaboration agreement with Genentech Inc., a
member of the Roche Group, to investigate the combination of
BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies
for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can
review the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated
on Facebook, Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
tsipihai5@gmail.com
SOURCE BioLineRx Ltd